The SHINE-CTO Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-31

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Design: Single center, double-blind, sham-controlled trial that will randomize symptomatic patients with a coronary chronic total occlusion (CTO) to CTO percutaneous coronary intervention (PCI) or a sham procedure. All patients will receive optimal medical therapy.

Treatment:CTO PCI, as per standard clinical practice.

Control: Patients randomized to sham-procedure will undergo only bilateral arterial access, without angiography or PCI being performed.

Secondary Endpoints: (1) Greater improvement in SAQ-7 Summary scores during the entire duration of follow-up (6 months) using a repeated measures analysis (2) Greater improvement in individual components of patients' health status (3) Greater improvement in exercise capacity (4) Similar incidence of major adverse cardiac events (MACE), both peri-procedural and long-term

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Thrombus Aspiration During PCI After Thrombolysis in STEMI

NCT06654453

ST-segment Elevation Myocardial Infarction

NOT_YET_RECRUITING NA

The First-In-Man Use of Coronary Sinus Balloon Pump in STEMI Patients Treated by Primary PCI

NCT07082153

STEMI

NOT_YET_RECRUITING NA

Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in ST-Elevation Myocardial Infarction (STEMI)

NCT01324453

Acute Myocardial Infarction

COMPLETED PHASE1/PHASE2

AngioJET Thrombectomy and STENTing for Treatment of Acute Myocardial Infarction

NCT00275990

Myocardial Infarction

COMPLETED PHASE4

ShenFu Injection for Myocardial Protection in Patients With Acute ST Segment Elevation Myocardial Infarction

NCT02709798

Myocardial Infarction

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease Chronic Total Occlusion of Coronary Artery Percutaneous Transluminal Coronary Angioplasty

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PCI of CTO

Intervention: PCI of CTO (Chronic Total Occlusion Percutaneous Coronary Intervention) Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI), as per standard clinical practice. Hospitalized overnight after the procedure, with post procedure monitoring practices as per standard of care for PCI. CTO PCI patients will receive blinded clopidogrel 75 mg daily for 6 months.

Group Type ACTIVE_COMPARATOR

Chronic Total Occlusion Percutaneous Coronary Intervention

Intervention Type PROCEDURE

Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI), as per standard clinical practice

Sham Procedure

Intervention: Sham procedure Subjects will be blinded to randomization assignment using a combination of conscious sedation and sensory isolation (e.g., blindfold and noise isolation). Control subjects will only undergo a "Sham procedure", wherein they will undergo bilateral arterial access, without angiography or PCI being performed. Hospitalized overnight after the procedure, with post procedure monitoring practices as per standard of care for PCI. Sham group will receive blinded placebo clopidogrel for 6 months.

Group Type SHAM_COMPARATOR

Sham Procedure

Intervention Type PROCEDURE

Sham Procedure: Bilateral arterial access, without angiography or PCI being performed

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Chronic Total Occlusion Percutaneous Coronary Intervention

Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI), as per standard clinical practice

Intervention Type PROCEDURE

Sham Procedure

Sham Procedure: Bilateral arterial access, without angiography or PCI being performed

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 years or greater
* Willing and able to give informed consent. The patients must be able to comply with study procedures and follow-up.
* Referred for clinically-indicated CTO PCI
* Optimal medical therapy (at least two anti-anginal medications at maximum tolerated doses, aspirin, and statin)

Exclusion Criteria

* Coexisting conditions that limit life expectancy to less than 6 months or that could affect a patient's compliance with the protocol
* Recent (\<7 days) acute myocardial infarction
* Patient has no symptoms related to the CTO
* Known allergy to aspirin or clopidogrel
* Increased risk of bleeding (need for warfarin, oral Xa inhibitor, or thrombin inhibitor administration, recent \[within 30 days\] major bleed, known bleeding diathesis or coagulation disorder)
* Positive pregnancy test or breast-feeding
* Chronic kidney disease, defined as serum creatinine \> 2.5 mg/dL
* Severe peripheral arterial disease limiting exercise capacity

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No